{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T17:31:45Z","timestamp":1783186305405,"version":"3.54.6"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12072-025-10860-0","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T02:51:24Z","timestamp":1754362284000},"page":"1412-1427","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of targeted therapy and immune checkpoint inhibitors in patients with advanced or metastatic biliary tract cancer: a meta-analysis of and sequential analysis of trials"],"prefix":"10.1007","volume":"19","author":[{"given":"Tinghui","family":"Mao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"issue":"10272","key":"10860_CR1","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet. 2021;397(10272):428\u2013444","journal-title":"Lancet"},{"issue":"2","key":"10860_CR2","doi-asserted-by":"publisher","first-page":"293","DOI":"10.21037\/jgo.2016.10.01","volume":"8","author":"DH Ahn","year":"2017","unstructured":"Ahn DH, Bekaii-Saab T. Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications. J Gastrointest Oncol. 2017;8(2):293\u2013301","journal-title":"J Gastrointest Oncol"},{"issue":"1","key":"10860_CR3","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/annonc\/mdv483","volume":"27","author":"J Bridgewater","year":"2016","unstructured":"Bridgewater J, Lopes A, Wasan H, Malka D, Jensen L, Okusaka T, et al. Prognostic factors for progression-free and overall survival in advanced biliary tract cancer. Ann Oncol. 2016;27(1):134\u2013140","journal-title":"Ann Oncol"},{"issue":"9","key":"10860_CR4","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1158\/2159-8290.CD-17-0245","volume":"7","author":"JW Valle","year":"2017","unstructured":"Valle JW, Lamarca A, Goyal L, Barriuso J, Zhu AX. New horizons for precision medicine in biliary tract cancers. Cancer Discov. 2017;7(9):943\u2013962","journal-title":"Cancer Discov"},{"issue":"12","key":"10860_CR5","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1200\/JCO.18.02178","volume":"37","author":"RT Shroff","year":"2019","unstructured":"Shroff RT, Kennedy EB, Bachini M, Bekaii-Saab T, Crane C, Edeline J, et al. Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline. J Clin Oncol. 2019;37(12):1015\u20131027","journal-title":"J Clin Oncol"},{"issue":"16","key":"10860_CR6","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1200\/JCO.2011.40.5381","volume":"30","author":"AM Horgan","year":"2012","unstructured":"Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol. 2012;30(16):1934\u20131940","journal-title":"J Clin Oncol"},{"issue":"14","key":"10860_CR7","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273\u20131281","journal-title":"N Engl J Med"},{"issue":"3","key":"10860_CR8","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2206834","volume":"388","author":"L Goyal","year":"2023","unstructured":"Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, et al. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med. 2023;388(3):228\u2013239","journal-title":"N Engl J Med"},{"issue":"1","key":"10860_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","volume":"38","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1\u201310","journal-title":"J Clin Oncol"},{"key":"10860_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082039","author":"S Chakrabarti","year":"2020","unstructured":"Chakrabarti S, Kamgar M, Mahipal A. Targeted therapies in advanced biliary tract cancer: an evolving paradigm. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12082039","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10860_CR11","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/jhbp.1219","volume":"30","author":"T Ioka","year":"2023","unstructured":"Ioka T, Kanai M, Kobayashi S, Sakai D, Eguchi H, Baba H, et al. Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA). J Hepatobiliary Pancreat Sci. 2023;30(1):102\u2013110","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"10860_CR12","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535","journal-title":"BMJ"},{"key":"10860_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898","journal-title":"BMJ"},{"key":"10860_CR14","unstructured":"GDT G. GRADEpro guideline development tool [software] McMaster university and evidence prime. https:\/\/www.gradepro.org\/. Accessed September 15, 2024. 2024."},{"key":"10860_CR15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16","journal-title":"Trials"},{"issue":"7414","key":"10860_CR16","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u2013560","journal-title":"BMJ"},{"issue":"4","key":"10860_CR17","first-page":"719","volume":"22","author":"N Mantel","year":"1959","unstructured":"Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719\u2013748","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10860_CR18","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177\u2013188","journal-title":"Control Clin Trials"},{"issue":"7109","key":"10860_CR19","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u2013634","journal-title":"BMJ"},{"issue":"4","key":"10860_CR20","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"CB Begg","year":"1994","unstructured":"Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088\u20131101","journal-title":"Biometrics"},{"issue":"1","key":"10860_CR21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12874-017-0315-7","volume":"17","author":"J Wetterslev","year":"2017","unstructured":"Wetterslev J, Jakobsen JC, Gluud C. Trial sequential analysis in systematic reviews with meta-analysis. BMC Med Res Methodol. 2017;17(1):39","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"10860_CR22","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S2468-1253(22)00043-7","volume":"7","author":"DY Oh","year":"2022","unstructured":"Oh DY, Lee KH, Lee DW, Yoon J, Kim TY, Bang JH, et al. Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study. Lancet Gastroenterol Hepatol. 2022;7(6):522\u2013532","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10860_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100417","volume":"7","author":"C Zhou","year":"2022","unstructured":"Zhou C, O\u2019Connor J, Backen A, Valle JW, Bridgewater J, Dive C, et al. Plasma Tie2 trajectories identify vascular response criteria for VEGF inhibitors across advanced biliary tract, colorectal and ovarian cancers. ESMO Open. 2022;7(2): 100417","journal-title":"ESMO Open"},{"issue":"10","key":"10860_CR24","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1016\/S1470-2045(21)00409-5","volume":"22","author":"JW Valle","year":"2021","unstructured":"Valle JW, Vogel A, Denlinger CS, He AR, Bai LY, Orlova R, et al. Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study. Lancet Oncol. 2021;22(10):1468\u20131482","journal-title":"Lancet Oncol"},{"issue":"6","key":"10860_CR25","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(6):796\u2013807","journal-title":"Lancet Oncol"},{"issue":"8","key":"10860_CR26","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","volume":"9","author":"DY Oh","year":"2024","unstructured":"Oh DY, He AR, Bouattour M, Okusaka T, Qin S, Chen LT, et al. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024;9(8):694\u2013704","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"10860_CR27","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1093\/annonc\/mdv035","volume":"26","author":"JS Chen","year":"2015","unstructured":"Chen JS, Hsu C, Chiang NJ, Tsai CS, Tsou HH, Huang SF, et al. A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer. Ann Oncol. 2015;26(5):943\u2013949","journal-title":"Ann Oncol"},{"issue":"9","key":"10860_CR28","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.annonc.2020.05.018","volume":"31","author":"A Demols","year":"2020","unstructured":"Demols A, Borbath I, Van den Eynde M, Houbiers G, Peeters M, Marechal R, et al. Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced\/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial. Ann Oncol. 2020;31(9):1169\u20131177","journal-title":"Ann Oncol"},{"key":"10860_CR29","doi-asserted-by":"crossref","unstructured":"Oh DY, Ruth He A, Qin S, Chen LT, Okusaka T, Vogel A, Kim JW, Suksombooncharoen T, Ah Lee M, Kitano M, et al. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evid. 2022;1(8):EVIDoa2200015.","DOI":"10.1056\/EVIDoa2200015"},{"issue":"11","key":"10860_CR30","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","volume":"7","author":"AX Zhu","year":"2021","unstructured":"Zhu AX, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, et al. Final overall survival efficacy results of Ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial. JAMA Oncol. 2021;7(11):1669\u20131677","journal-title":"JAMA Oncol"},{"issue":"10391","key":"10860_CR31","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10391):1853\u20131865","journal-title":"Lancet"},{"issue":"2","key":"10860_CR32","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1470-2045(11)70301-1","volume":"13","author":"J Lee","year":"2012","unstructured":"Lee J, Park SH, Chang HM, Kim JS, Choi HJ, Lee MA, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2012;13(2):181\u2013188","journal-title":"Lancet Oncol"},{"issue":"4","key":"10860_CR33","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/cncr.29778","volume":"122","author":"F Leone","year":"2016","unstructured":"Leone F, Marino D, Cereda S, Filippi R, Belli C, Spadi R, et al. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: a randomized phase 2 trial (Vecti-BIL study). Cancer. 2016;122(4):574\u2013581","journal-title":"Cancer"},{"key":"10860_CR34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejca.2017.12.028","volume":"92","author":"A Vogel","year":"2018","unstructured":"Vogel A, Kasper S, Bitzer M, Block A, Sinn M, Schulze-Bergkamen H, et al. PICCA study: panitumumab in combination with cisplatin\/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study. Eur J Cancer. 2018;92:11\u201319","journal-title":"Eur J Cancer"},{"issue":"8","key":"10860_CR35","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S1470-2045(14)70212-8","volume":"15","author":"D Malka","year":"2014","unstructured":"Malka D, Cervera P, Foulon S, Trarbach T, de la Fouchardi\u00e8re C, Boucher E, et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol. 2014;15(8):819\u2013828","journal-title":"Lancet Oncol"},{"key":"10860_CR36","doi-asserted-by":"publisher","DOI":"10.1172\/JCI152670","author":"M Yarchoan","year":"2021","unstructured":"Yarchoan M, Cope L, Ruggieri AN, Anders RA, Noonan AM, Goff LW, et al. Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers. J Clin Invest. 2021. https:\/\/doi.org\/10.1172\/JCI152670","journal-title":"J Clin Invest"},{"issue":"18","key":"10860_CR37","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.1016\/j.ejca.2014.09.013","volume":"50","author":"M Moehler","year":"2014","unstructured":"Moehler M, Maderer A, Schimanski C, Kanzler S, Denzer U, Kolligs FT, et al. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme. Eur J Cancer. 2014;50(18):3125\u20133135","journal-title":"Eur J Cancer"},{"issue":"8","key":"10860_CR38","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/S1470-2045(15)00139-4","volume":"16","author":"JW Valle","year":"2015","unstructured":"Valle JW, Wasan H, Lopes A, Backen AC, Palmer DH, Morris K, et al. Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. Lancet Oncol. 2015;16(8):967\u2013978","journal-title":"Lancet Oncol"},{"key":"10860_CR39","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae265","author":"A Reichinger","year":"2024","unstructured":"Reichinger A, Essl L, Kerschner P, Burghofer J, Webersinke G, Rumpold H, et al. Exceptional sustained long-term complete response to Tepotinib in a MET-amplified advanced intrahepatic biliary tract cancer failing Durvalumab plus Cisplatin and Gemcitabine. Oncologist. 2024. https:\/\/doi.org\/10.1093\/oncolo\/oyae265","journal-title":"Oncologist"},{"issue":"8","key":"10860_CR40","doi-asserted-by":"publisher","first-page":"e1051","DOI":"10.1093\/oncolo\/oyae076","volume":"29","author":"Y Kim","year":"2024","unstructured":"Kim Y, Jee S, Kim H, Paik SS, Choi D, Yoo SH, et al. EGFR, HER2, and MET gene amplification and protein expression profiles in biliary tract cancer and their prognostic significance. Oncologist. 2024;29(8):e1051\u2013e1060","journal-title":"Oncologist"},{"issue":"2","key":"10860_CR41","first-page":"3","volume":"132","author":"MA Lowery","year":"2017","unstructured":"Lowery MA, Abou-Alfa GK, Burris H. Phase 1 study of AG-120, an IDH1 mutant enzyme inhibitor: results from the cholangiocarcinoma dose escalation and expansion cohorts. Safety. 2017;132(2):3","journal-title":"Safety"},{"key":"10860_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.777617","volume":"11","author":"Y Wang","year":"2021","unstructured":"Wang Y, Chen T, Li K, Mu W, Liu Z, Shi A, et al. Recent Advances in the Mechanism Research and Clinical Treatment of Anti-Angiogenesis in Biliary Tract Cancer. Front Oncol. 2021;11: 777617","journal-title":"Front Oncol"},{"issue":"6","key":"10860_CR43","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1634\/theoncologist.2014-0465","volume":"20","author":"Y Zhao","year":"2015","unstructured":"Zhao Y, Adjei AA. Targeting angiogenesis in cancer therapy: moving beyond vascular endothelial growth factor. Oncologist. 2015;20(6):660\u2013673","journal-title":"Oncologist"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-025-10860-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-025-10860-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-025-10860-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T17:20:22Z","timestamp":1766078422000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-025-10860-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10860"],"URL":"https:\/\/doi.org\/10.1007\/s12072-025-10860-0","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,5]]},"assertion":[{"value":"26 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}